Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key me... ...

The CNBC app, global market news in one place. Customizable sections and personalized alerts, stocks tracking, interactive charts and market insights, all in your hands. Stay connected, stay informed.Download the CNBC app today. >> Welcome to Sportbox Europe. I'm Karen show with Juliana Tatlebomb.These are your headlines in corporate news. Nevada says it's well on track to achieve its guidance for the year as Q3 operating income surges by a quarter, countering the impact of generic drug erosion in the Unite ...

Core Insights - Swiss drugmaker Novartis is planning to enhance its direct-to-patient platform by adding more medicines, with the platform set to launch in the U.S. next month [1] Company Developments - CEO Vas Narasimhan indicated that the company is actively exploring options for expanding its medicine offerings on the new platform [1]

瑞士制药巨头诺华制药(NVS.US)盘前跌3%，报125.27美元。消息上，诺华第三季度销售净额139.1亿美 元，预估138.8亿美元；核心每股收益2.25美元，预估2.26美元；核心净利润43.3亿美元，预估44.2亿美 元。诺华重申了其2025年全年指引，维持高个位数的销售增长和低两位数的核心运营利润增长预期。 (格隆汇) | NVS 诺华制药 | | | | --- | --- | --- | | 129.140 ↓ -1.220 -0.94% | | 收盘价 10/27 15:59 美东 | | 125.270 -3.870 -3.00% | | 盘前价 10/28 04:19 美东 | | = 71 4 5 × × ■ ♥ 白选 | | ● 快捷交易 | | 最高价 130.170 | 开盘价 128.000 | 成交量 257.89万 | | 最低价 127.080 | 昨收价 130.360 | 成交额 3.32亿 | | 平均价 128.922 | 市空室 IM 18.83 | 总市值 2499.96亿(m) | | 振 幅 2.37% | 市盈率(静) 22.00 | 总股本 19.36亿 ...

Core Insights - Novartis is acquiring Avidity Biosciences for approximately $12 billion, marking its largest deal in a decade, to enhance its drug pipeline and offset competition from generics [2] - The company reported a 7% increase in third-quarter net sales to $13.9 billion, with operating income rising 27% to $5.46 billion, slightly exceeding analyst expectations [3] - Novartis has maintained its sales growth guidance at a "high single digit" percentage and adjusted operating income growth at a "low teens" percentage despite market pressures [5] Financial Performance - The third-quarter net sales reached $13.9 billion, reflecting a 7% increase [3] - Operating income for the quarter increased by 27% to $5.46 billion, surpassing analyst expectations [3] - Key drugs such as Kisqali, Pluvicto, Scemblix, and Kesimpta contributed to high double-digit revenue growth [4] Strategic Moves - Novartis has been actively acquiring companies, with over 35 acquisitions in the past year to strengthen its market position [2] - The acquisition of Avidity is expected to provide access to promising experimental drugs, with two of Avidity's leading drugs projected to generate billions in sales by 2030 [1] - The company is focused on continuous acquisition to find the next "great asset" in the pharmaceutical sector [2] Market Challenges - Novartis faces challenges from generics competition, which has negatively impacted revenue by 7 percentage points due to loss of exclusivity for key drugs [6] - Revenue deductions in the U.S. due to pricing adjustments contributed an additional negative impact of 2 percentage points [6] - The company is closely monitoring global tariff updates and U.S. drug pricing policies that could affect its operations [6][7] Future Outlook - Analysts expect Novartis to potentially enter similar "most favoured nation" agreements as Pfizer and AstraZeneca, which could impact earnings from 2026 onwards [8] - Novartis has committed to eliminating price differentials between U.S. and other industrialized nations for its drugs [8] - The company is not expected to be affected by a 100% tariff on branded pharmaceuticals due to its significant investment in U.S. infrastructure [9]

Core Insights - The industrial-gas supplier reported a revenue increase of 1.9% on a comparable basis and reaffirmed its outlook for 2025 [1] Group 1 - Revenue rose by 1.9% on a comparable basis [1] - The company backed its outlook for 2025 [1]

Core Insights - Novartis has initiated a wave of acquisitions this year, with a focus on enhancing its drug pipeline and compensating for revenue declines from key therapies due to patent expirations [1][2] - The company reported a 6% increase in operating profit, reaching $5.46 billion in Q3, slightly above analyst expectations of $5.4 billion [1] - Q3 revenue was $13.91 billion, representing an 8.4% year-over-year growth, exceeding forecasts, while adjusted EPS was $2.25, falling short of expectations by $0.06 [1] Financial Performance - Novartis' Q3 operating profit adjusted for special items increased to $5.46 billion, surpassing analyst expectations [1] - The company has raised its annual performance outlook twice this year, maintaining its 2025 financial guidance with projected sales growth in the "mid-high single digits" and adjusted operating profit growth in the "low double digits" [1] Product Performance - The heart drug Entresto, which lost patent protection this year, generated $1.88 billion in sales during Q3, with total sales expected to reach $7.82 billion globally in 2024 [1] - Analysts had anticipated Q3 sales for Entresto to be $1.77 billion [1] - The psoriasis treatment drug Cosentyx faced competition from AbbVie's Bimzelx, with sales remaining flat at $1.7 billion year-over-year [2] - The breast cancer drug Kisqali, launched last year, achieved sales of $1.33 billion [2] Acquisition Strategy - Novartis is actively pursuing acquisitions and licensing deals valued at $30 billion, including a $12 billion acquisition of U.S. biotech company Avidity [1]

Core Insights - The drugmaker reported a third-quarter profit of $3.93 billion, driven by increased sales of key drugs which helped to mitigate the impact of patent expirations [1] Financial Performance - The third-quarter profit reached $3.93 billion, indicating strong financial performance despite challenges [1] - Higher sales for key drugs were a significant factor contributing to the profit [1] Market Impact - The company successfully offset losses from patent expirations through strategic sales increases [1]

Core Viewpoint - Giant Mining Corp. supports the White House's proclamation aimed at providing regulatory relief to U.S. copper smelting facilities, which is seen as a step to enhance American mineral security and reduce dependence on foreign processing [1][6]. Regulatory Relief - The proclamation extends compliance timelines by two years for specific stationary sources, which helps preserve critical U.S. copper processing capacity amid rising strategic demand [4]. - The White House's action is intended to avoid near-term disruptions at designated U.S. smelters while maintaining environmental oversight [6]. Company Position - The CEO of Giant Mining emphasizes the importance of American copper and supports policies that responsibly advance domestic copper supply [5]. - The company is committed to responsible resource development to ensure long-term U.S. mineral independence and applies best practices in exploration and environmental management [7]. Project Overview - Giant Mining's flagship asset is the Majuba Hill Copper-Silver-Gold Project located in Nevada, which is recognized as a mining-friendly jurisdiction [10]. - The project spans 9,684 acres and is well-supported by existing infrastructure, providing significant cost advantages [7]. - Historical production and extensive drilling (approximately 89,395 feet) indicate the project's potential, with a replacement value of drilling estimated at USD 12.1 million [7]. Market Demand - The growing global demand for critical metals, driven by initiatives like the Green New Deal, necessitates substantial amounts of copper, silver, and gold for electric vehicles and renewable energy infrastructure [8].

Core Insights - The largest bank in the eurozone by assets reported a net profit that is 6.1% higher than the previous year [1] Company Summary - The bank's net profit reflects a positive growth trend compared to the same period last year, indicating strong financial performance [1]